Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Community-Acquired Pneumonia
Data released from phase III trial comparing 5-, 7-day Factive treatment of CAP
October 23rd, 2005
Data from the study of Oscient Pharmaceuticals' (OSCI) U.S. Food & Drug Administration (FDA)-approved fluoroquinolone antibiotic, Factive (gemifloxacin mesylate) tablets, for the potential 5-day treatment of mild-to-moderate community-acquired pneumonia (CAP) were presented in a poster at the second International Conference on Community-Acquired Pneumonia in Montreal, Quebec, Canada. In a noninferiority phase III trial, a 5-day course of therapy with Factive was shown to be as effective as the FDA-approved 7-day course of treatment, with both arms displaying excellent clinical response rates. Further, data showed that the bacteriological and radiologic success rates...
Source: Medical Letter on the CDC & FDA (2005-10-23)
|
